U
Urs Lüthi
Researcher at University of Zurich
Publications - 18
Citations - 1585
Urs Lüthi is an academic researcher from University of Zurich. The author has contributed to research in topics: Amyloid precursor protein secretase & Docking (molecular). The author has an hindex of 11, co-authored 16 publications receiving 1386 citations.
Papers
More filters
Journal ArticleDOI
Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis
Yingdi Wang,Masanori Nakayama,Mara E. Pitulescu,Tim S. Schmidt,Magdalena L. Bochenek,Magdalena L. Bochenek,Akira Sakakibara,Susanne Adams,Susanne Adams,Alice Davy,Urban Deutsch,Urs Lüthi,Alcide Barberis,Laura E. Benjamin,Taija Makinen,Catherine D. Nobes,Ralf H. Adams,Ralf H. Adams +17 more
TL;DR: It is shown with genetic experiments in mouse and zebrafish that ephrin-B2, a transmembrane ligand for Eph receptor tyrosine kinases, promotes sprouting behaviour and motility in the angiogenic endothelium, and shows that full VEGFR3 signalling is coupled to receptor internalization.
Journal ArticleDOI
Plant orthologs of p300/CBP: conservation of a core domain in metazoan p300/CBP acetyltransferase-related proteins
TL;DR: Interestingly, homology between animal and plant p300/CBP is largely restricted to a C-terminal segment, about 600 amino acids in length, which encompasses acetyltransferase and E1A-binding domains.
Journal ArticleDOI
Functional analysis of the p300 acetyltransferase domain: the PHD finger of p300 but not of CBP is dispensable for enzymatic activity.
TL;DR: Unexpectedly, it is found that the PHD finger of p300, but not of CBP, is dispensable for AT activity, which provides evidence for structural differences between p300 and CBP that may in part underlie a previously reported functional specialization of the two proteins.
Journal ArticleDOI
In Silico Discovery of β-Secretase Inhibitors
TL;DR: An in silico screening approach consisting of fragment-based docking, ligand conformational search by a genetic algorithm, and evaluation of free energy of binding was used to identify low-molecular-weight inhibitors of BACE-1, which has emerged as an important but difficult protein target.
Journal ArticleDOI
Discovery of cell-permeable non-peptide inhibitors of beta-secretase by high-throughput docking and continuum electrostatics calculations.
Danzhi Huang,Urs Lüthi,Peter Kolb,Karin Edler,Marco Cecchini,Stephan Valentin Audétat,and Alcide Barberis,Amedeo Caflisch +7 more
TL;DR: The phenylureathiadiazole 2 and the diphenylurea derivative 3 are promising lead compounds for beta-secretase inhibition.